Markets:

Overview

News

Currencies

International

Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

40.50 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

June 22, 2026

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether RAMP, NEE, CNTA, GDOT are Obtaining Fair Deals for their Shareholders

May 27, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

May 11, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly ↗

April 27, 2026

Eli Lilly has more to offer than some investors realize.

Via The Motley Fool

Is This $6.3 Billion Deal a Game Changer for Eli Lilly? ↗

April 16, 2026

It's acquiring an asset with a very promising lead drug candidate.

Via The Motley Fool

Looks Like M&A Week in 3 Different Sectors ↗

April 08, 2026

Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry.

Via The Motley Fool

Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders

April 07, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders

April 07, 2026

From Ademi LLP

Via GlobeNewswire

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...

Via MarketMinute

Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine

April 06, 2026

In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...

Via MarketMinute

Topics Artificial Intelligence

Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience ↗

April 02, 2026

In a powerful demonstration of financial strength and strategic foresight, Eli Lilly and Company (NYSE: LLY) recently committed over $10 billion to two major initiatives in just a matter of days. While...

Via MarketBeat

Topics Artificial Intelligence

Halper Sadeh LLC is Investigating Whether APLS, CNTA, EQH, VYNE are Obtaining Fair Deals for their Shareholders

April 02, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Wall Street Ends a Rough Quarter With Its Best Day, Iran Hope Ignites the Rally ↗

April 01, 2026

Via Chartmill

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

March 31, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Why Centessa Stock Soared Today ↗

March 31, 2026

A pharma giant wants to buy the innovative drug developer.

Via The Motley Fool

Halper Sadeh LLC is Investigating Whether APLS, CNTA, BIRD, WBD are Obtaining Fair Deals for their Shareholders

March 31, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 31, 2026

Via Chartmill

Which stocks are experiencing notable movement on Tuesday? ↗

March 31, 2026

Via Chartmill

The market is filled with gapping stocks in Tuesday's session. ↗

March 31, 2026

Via Chartmill

The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals

March 31, 2026

Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience

March 31, 2026

Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY)....

Via Finterra

Topics Economy Intellectual Property

Discover the top movers in Tuesday's pre-market session. ↗

March 31, 2026

Via Chartmill

CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

March 31, 2026

From Halper Sadeh LLC

Via Business Wire

Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline ↗

February 26, 2026

One of these is not like the other.

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.

Via The Motley Fool

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

February 03, 2026

From Centessa Pharmaceuticals plc

Via GlobeNewswire

This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally ↗

February 01, 2026

Centessa Pharmaceuticals develops therapies for rare and serious diseases, advancing a pipeline of clinical-stage and emerging candidates.

Via The Motley Fool

Topics ETFs

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

January 14, 2026

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder

From Centessa Pharmaceuticals plc

Via GlobeNewswire

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

A full exit during a volatile stretch raises a sharper question than timing alone.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.